Keith Wheatley
Impact in
- Hematology top 0.01%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Genetics top 0.05%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 117
- Acute Myeloid Leukemia Research 106
- Multiple Myeloma Research and Treatments 23
- Chronic Myeloid Leukemia Treatments 23
- Genetics 40
- Myeloproliferative Neoplasms: Diagnosis and Treatment 21
- Co-authors
- Richard GrayAlan K. BurnettRichard PetoRichard DollI. L. G. SutherlandAnthony H. GoldstoneRobert K. HillsIan Hann
- Journals
- Blood (59 papers)Journal of Clinical Oncology (33 papers)British Journal of Haematology (30 papers)Cochrane Database of Systematic Reviews (11 papers)Trials (9 papers)
- Partner nations
- United KingdomFranceUnited States
In The Last Decade
Keith Wheatley
249 papers receiving 26.0k citations
Hit Papers
Peers
Comparison fields: 5 of 179
- Hematology 13.4k
- Genetics 4.8k
- Public Health, Environmental and Occupational Health 6.5k
- Neurology 2.8k
- Oncology 3.9k
Countries citing papers authored by Keith Wheatley
This map shows the geographic impact of Keith Wheatley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith Wheatley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith Wheatley more than expected).
Fields of papers citing papers by Keith Wheatley
This network shows the impact of papers produced by Keith Wheatley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith Wheatley. The network helps show where Keith Wheatley may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Keith Wheatley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2020 | 25 | |
| 3 | 2019 | 11 | |
| 4 | 2018 | 5 | |
| 5 | MOLECULAR PREDICTORS OF RESPONSE TO AZACITIDINE THERAPY: THE RESULTS OF THE UK TRIALS ACCELERATION PROGRAMME RAVVA STUDY | 2017 | 4 |
| 6 | 2013 | 289 | |
| 7 | 2013 | 27 | |
| 8 | 2010 | 78 | |
| 9 | 2008 | 147 | |
| 10 | Attempts to modulate chemoresistance in older patients with AML using PSC-833 - Results of the LRF AML14 trial | 2003 | 4 |
| 11 | Refinement of cytogenetic classification in AML: determination of prognostic significance of rare recurring chromosomal abnormalities amongst patients entered into the UK MRC AML 10 & 12 trials. | 2002 | 3 |
| 12 | Relationships between age at diagnosis, clinical features and outcome of therapy in children treated in the Medical Research Council trials for acute myeloid leukemia AML 10 and 12. | 2000 | 2 |
| 13 | The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the MRC AML 10 and 12 trials. | 2000 | 7 |
| 14 | Del(9q) AML: Clinical, cytological and cytogenetic characteristics and prognostic implications for patients entering the MRC AML trials. | 1999 | 2 |
| 15 | The importance of diagnostic cytogenetics in older patients with AML: Analysis of 922 patients entered into the MRC AML 11 trial. | 1999 | 5 |
| 16 | Outcome of acute myeloid leukaemias affecting core binding factor subunits: the UK MRC experience | 1997 | 1 |
| 17 | A simple, robust and highly predictive prognostic index for the determination of risk directed therapy in acute myeloid leukaemia (AML) derived from the United Kingdom medical research council (MRC) AML10 trial. | 1995 | 13 |
| 18 | Intensive chemotherapy with or without additional bone marrow transplantation in paediatric AML:Progress report on the MRC AML 10 trial | 1992 | 2 |
| 19 | Intensive chemotherapy with or without additional bone marrow transplantation in paediatric AML: progress report on the MRC AML 10 trial. Medical Research Council Working Party on Childhood Leukaemia. | 1992 | 3 |
| 20 | 1990 | 3 |
About Keith Wheatley
Keith Wheatley is a scholar working on Hematology, Genetics, Neurology, Public Health, Environmental and Occupational Health and Oncology, having authored 254 papers that have together received 27.0k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (106 papers), Acute Lymphoblastic Leukemia research (51 papers), Retinoids in leukemia and cellular processes (35 papers), Multiple Myeloma Research and Treatments (23 papers), Chronic Myeloid Leukemia Treatments (23 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (21 papers), Neuroblastoma Research and Treatments (19 papers) and Parkinson's Disease Mechanisms and Treatments (19 papers). The work is most often cited by research in Hematology (13.4k citations), Genetics (4.8k citations), Public Health, Environmental and Occupational Health (6.5k citations), Neurology (2.8k citations) and Oncology (3.9k citations). Keith Wheatley has collaborated with scholars based in United Kingdom, France and United States. Frequent co-authors include Richard Gray, Alan K. Burnett, Richard Peto, Richard Doll, I. L. G. Sutherland, Anthony H. Goldstone, Robert K. Hills, Ian Hann, David Grimwade and Helen M. Walker. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, Cochrane Database of Systematic Reviews and Trials.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.